Durham-based BioCryst Pharmaceuticals lands $35 million contract with CDC
BioCryst Pharmaceuticals Inc. has landed a $35 million contract with the Centers for Disease Control and Prevention.
Read More
biocryst
As BioCryst seeks to raise $57M, it receives FDA fast-track designation for drug
Biocryst, which recently failed to secure a merger and is now looking to raise $57.5 million, on Monday said it had received fast-track designation from the FDA for a drug it has under development.
Read More
After merger failure, BioCryst offers up to $57.5M in shares to fund new life
Just three weeks after scuttling plans to merge with a Pennsylvania company and move there, publicly traded Durham biotechnology company BioCryst Pharmaceuticals is selling up to $57.5 million in stock.
Read More
BioCryst keeps Durham HQ, workforce after marriage cancellation
BioCryst Senior Vice President and CFO Thomas Staab tells he North Carolina Biotechnology Center that the decision means it’s business as usual for BioCryst employees after a proposed merger fell through.
Read MoreBioCryst Pharma shareholders reject merger with Pennsylvania firm
Shareholders in BioCryst Pharmaceuticals rejected a merger with Pennsylvania-based Idera Pharmaceuticals in a special shareholders meeting on Tuesday.
Read More
BioCryst gets European approval of its flu treatment
It is a single intravenous infusion for the treatment of uncomplicated influenza in adults and children from the age of 2 years.
Read MoreLarge holder of Biocryst shares wants to scuttle merger with Idera Pharmaceuticals
A large shareholder in Biocryst Pharmaceuticals argues that the drug company’s proposed merger with another drug company undervalues its assets and wants to scuttle the deal
Read MoreBioCryst Pharmaceuticals to merge with Idera Pharma; firm to be based in Pennsylvania
Durham-based BioCryst Pharmaceuticals has signed a definitive merger agreement with Idera Pharmaceuticals. Biocryst board chair Bob Ingram will lead the board of the merged firm.
Read More
